Sulfasalazine intolerance. A retrospective survey of the reasons for discontinuing treatment with sulfasalazine in patients with chronic inflammatory bowel disease.
about
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitisOral 5-aminosalicylic acid for induction of remission in ulcerative colitisOral 5-aminosalicylic acid for induction of remission in ulcerative colitisOral 5-aminosalicylic acid for maintenance of remission in ulcerative colitisOmega 3 fatty acids (fish oil) for maintenance of remission in ulcerative colitisOral 5-aminosalicylic acid for maintenance of remission in ulcerative colitisOral 5-aminosalicylic acid for induction of remission in ulcerative colitisOral 5-aminosalicylic acid for induction of remission in ulcerative colitisMesalazine preparations for the treatment of ulcerative colitis: Are all created equal?Long-term treatment of rheumatoid arthritis with sulphasalazine, gold, or penicillamine: a comparison using life-table methods.A double blind comparative study of sulphasalazine and hydroxychloroquine in rheumatoid arthritis: evidence of an earlier effect of sulphasalazine.Medical treatment of inflammatory bowel disease: new therapies, new drugs.Long-term efficacy and safety of once-daily mesalazine granules for the treatment of active ulcerative colitis.Cost utility of inflammation-targeted therapy for patients with ulcerative colitis.Treatment of inflammatory bowel disease: a review of medical therapy.Review article: delivery and efficacy of topical 5-aminosalicylic acid (mesalazine) therapy in the treatment of ulcerative colitis.Current and emerging maintenance therapies for ulcerative colitis.Once-daily MMX mesalamine for the treatment of mild-to-moderate ulcerative colitis.Conventional drug therapy for inflammatory bowel disease.Mesalamine, but Not Sulfasalazine, Reduces the Risk of Colorectal Neoplasia in Patients with Inflammatory Bowel Disease: An Agent-specific Systematic Review and Meta-analysis.New Applications for Traditional Drugs in Inflammatory Bowel Disease: What Do Cochrane Reviews Tell Us?Design, Synthesis, and Testing of a Molecular Truck for Colonic Delivery of 5-Aminosalicylic Acid.Once versus divided daily dosing with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters.5-amino-salicylate in the management of inflammatory bowel disease.
P2860
Q24185774-7977100E-99B0-47C8-8E61-8F3E624287DCQ24185876-F87EF29A-C874-4362-A896-22EF3AA15F05Q24198024-A2320278-0BF0-45A7-8E68-E0FB2E2C83E1Q24198786-B4443A84-F036-4341-866F-D3A6BF2C943BQ24244006-6655AD68-5A26-4399-B42C-BB15E529989CQ24246085-22A3D58A-49DB-41A8-B6F5-0E28CF299E96Q24246220-D1F2F394-3B81-4B77-9CB6-C915F0F167F9Q24248026-27AB70D5-61A4-4271-8713-360C4F660050Q26777634-52803CAE-71A1-4480-82A0-BB8BDE02F861Q33557284-EEB949CC-64AA-4228-A570-71D60A010FA1Q33561669-A2B2E50D-5300-4684-8FF2-3794C737F977Q34100485-8D8159B6-5402-4C20-97E3-1C4A21FA8C4AQ34273329-8AE0A790-A8A2-4C88-BF6B-1B649509F1FEQ36815176-576C04E7-7E47-4F20-A1EB-6E8AA2715D21Q37058862-956C80E0-8E2B-48E8-A84B-ACE6D4ED147DQ37850826-9FCC9620-29B1-410F-8462-7360348E62E6Q38197719-8A0A2C46-346E-4DF2-A098-77BC42B92727Q38288749-89E4BB07-B6F6-4A7D-B981-1318AF3D6B7AQ38293796-E4CB5836-FAF6-4698-B6A1-DFF918FA903CQ38571099-561E6AF3-F8B6-431A-82BD-EDB88A391689Q38625992-6E9E2F5B-AA5D-4EBA-B8BB-D2A74CB4AB94Q41852528-F127274C-43A6-462F-8657-D2BB3D73147BQ43514773-15A63872-9378-4EDE-9845-9D54E204276AQ44468368-C9D94A3E-2791-472E-8D05-64948CCD1EBA
P2860
Sulfasalazine intolerance. A retrospective survey of the reasons for discontinuing treatment with sulfasalazine in patients with chronic inflammatory bowel disease.
description
1982 nî lūn-bûn
@nan
1982年の論文
@ja
1982年学术文章
@wuu
1982年学术文章
@zh-cn
1982年学术文章
@zh-hans
1982年学术文章
@zh-my
1982年学术文章
@zh-sg
1982年學術文章
@yue
1982年學術文章
@zh
1982年學術文章
@zh-hant
name
Sulfasalazine intolerance. A r ...... ic inflammatory bowel disease.
@en
type
label
Sulfasalazine intolerance. A r ...... ic inflammatory bowel disease.
@en
prefLabel
Sulfasalazine intolerance. A r ...... ic inflammatory bowel disease.
@en
P2860
P1476
Sulfasalazine intolerance. A r ...... ic inflammatory bowel disease.
@en
P2860
P304
P356
10.3109/00365528209182073
P577
1982-04-01T00:00:00Z